Sterling Investment Advisors, Ltd. Curis Inc Transaction History

Sterling Investment Advisors, Ltd.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	BUY	$0.71 - $2.43 $710 - $2,430	1,000 Added 33.33%	4,000 $4,000
Q4 2021 Feb 02, 2022	BUY	$4.45 - $8.09 $13,350 - $24,270	3,000 New	3,000 $14,000
Q3 2021 Nov 09, 2021	SELL	$6.94 - $8.85 $20,820 - $26,550	-3,000 Closed	0 $0
Q2 2021 Jul 29, 2021	BUY	$7.45 - $16.27 $3,725 - $8,135	500 Added 20.0%	3,000 $24,000
Q1 2021 May 04, 2021	SELL	$8.78 - $12.8 $21,950 - $32,000	-2,500 Reduced 50.0%	2,500 $28,000
Q4 2020 Jan 21, 2021	SELL	$1.08 - $8.2 $10,800 - $82,000	-10,000 Reduced 66.67%	5,000 $41,000
Q2 2020 Jul 24, 2020	BUY	$0.63 - $1.7 $1,260 - $3,400	2,000 Added 15.38%	15,000 $18,000
Q1 2020 Apr 30, 2020	BUY	$0.67 - $1.85 $1,005 - $2,775	1,500 Added 13.04%	13,000 $9,000
Q4 2019 Feb 10, 2020	BUY	$1.36 - $2.44 $2,040 - $3,660	1,500 Added 15.0%	11,500 $19,000
Q3 2019 Oct 15, 2019	BUY	$1.74 - $2.83 $4,350 - $7,075	2,500 Added 33.33%	10,000 $22,000
Q2 2019 Aug 06, 2019	BUY	$1.36 - $2.35 $2,040 - $3,525	1,500 Added 25.0%	7,500 $14,000
Q4 2018 Jan 18, 2019	BUY	$0.62 - $2.25 $3,100 - $11,250	5,000 Added 500.0%	6,000 $4,000
Q3 2018 Nov 09, 2018	BUY	$1.38 - $1.94 $1,380 - $1,940	1,000 New	1,000 $2,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Sterling Investment Advisors, Ltd., based on Form 13F filings with the SEC.

Stay updated on Sterling Investment Advisors, Ltd. with notifications on news.